Drug Profile
MK 2637
Alternative Names: MK-2637Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in Germany (PO, Capsule)
- 12 Dec 2005 Preclinical trials in Psychiatric disorders (unspecified route)